Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.
The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Chitra Venkatasubramanian, MBBS, MD, MSc.
- Peter D'Souza, MD
- Anna Finley Caulfield, MD
- James Quinn, MD
- drug : Placebo
- drug : Progesterone
Phase: Phase 3
Ages Eligible For Study:
- Moderate to severe brain injury (GCS 12-4) - Age 18 years or older - Blunt, closed head injury - Study drug initiated within 4 hours of injury